Cabozantinib demonstrated a lower overall cardiovascular adverse event signal (ROR 0.70; 95% CI 0.66-0.75) compared with sunitinib (ROR 0.87; 95% CI 0.82-0.91) in renal cell carcinoma.
Observational
Does cabozantinib have a different sex-specific adverse event profile and cardiovascular toxicity compared to sunitinib in patients with renal cell carcinoma?
In a real-world pharmacovigilance study, cabozantinib showed sex-specific safety differences and a comparatively favorable cardiovascular profile compared to sunitinib in patients with renal cell carcinoma.
Effect estimate: ROR 0.70 (95% CI 0.66-0.75)
BACKGROUND: Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in advanced renal cell carcinoma (RCC). However, real-world evidence regarding its safety profile, particularly sex-specific adverse events (AEs) and cardiovascular toxicity, remains limited. METHODS: A retrospective pharmacovigilance study was performed using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from Q2 2016 to Q2 2025. Reports listing cabozantinib as the primary suspected drug and RCC as the indication were included. Disproportionality analyses using Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) were conducted to identify safety signals. Sex-specific differences were evaluated using a modified 2 × 2 contingency table. Time-to-onset (TTO) was assessed with Weibull distribution modeling. Cardiovascular toxicity was further analyzed using standardized MedDRA queries (SMQs) and compared with sunitinib. RESULTS: < 1, indicating an early-onset pattern. Females showed higher reporting of gastrointestinal and dermatologic AEs, while males had higher frequencies of severe outcomes, including acute myocardial infarction. Cabozantinib demonstrated a lower overall cardiovascular AE signal (ROR = 0.70, 95% CI: 0.66-0.75) compared with sunitinib (ROR = 0.87, 95% CI: 0.82-0.91). CONCLUSIONS: This real-world study highlights sex-specific safety differences, early AE onset, and a comparatively favorable cardiovascular profile of cabozantinib, supporting individualized monitoring strategies in RCC treatment.
Bao et al. (2026) conducted an observational in Renal cell carcinoma (RCC). Cabozantinib vs. Sunitinib was evaluated on Overall cardiovascular adverse event signal (ROR 0.70, 95% CI 0.66-0.75). Cabozantinib demonstrated a lower overall cardiovascular adverse event signal (ROR 0.70; 95% CI 0.66-0.75) compared with sunitinib (ROR 0.87; 95% CI 0.82-0.91) in renal cell carcinoma.